宫颈癌2种新辅助化疗方案血清EZH2和HGF的表达水平

摘要

目的 探讨宫颈癌2种新辅助化疗方案血清EZH2、HGF的表达水平及其疗效.方法 收集2015年1月-2016年2月在新疆医科大学附属肿瘤医院确诊为宫颈癌的患者54例,按照患者意愿选择接受宫颈癌术前新辅助化疗的方案,分为接受TP方案者(TP组)27例和接受PVB方案者(PVB组)27例.所有留置的血液标本由新疆医科大学附属肿瘤医院肿瘤研究所标本库存储、处理.使用人HGF ELISA、人EZH2 ELISA检测化疗前、后血清EZH2和HGF的表达水平.结果 PVB组患者化疗后血清EZH2表达水平明显低于化疗前,PVB组化疗后血清EZH2表达水平明显低于TP组,差异均有统计学意义(P<0.05).结论 宫颈癌PVB新辅助化疗可能通过降低血清中EZH2的表达水平起效,促使病灶缩小,可作为观察宫颈癌新辅助化疗前后疗效评价的一个指标.%Objective To investigate the expression of serum EZH2 and HGF in two neoadjuvant chemotherapy protocols for cervical cancer and its efficacy.Methods A total of 54 patients diagnosed with cervical cancer were collected in the Tumor Hospital of Xinjiang Medical University from January 2015 to February-2016.According to whether the patient''s desire to choose the preoperative neoadjuvant chemotherapy for cervical cancer,the patients was divided into TP group and PVB group,with each having 27 patients.All corresponding blood specimens were stored and processed by Cancer Research Institute,Affiliated Tumor Hospital of Xinjiang Medical University.The levels of serum EZH2 and HGF were detected before and after chemotherapy using ELISA method.Results The level of serum EZH2 after chemotherapy was significantly lower than that before chemotherapy,and the level of serum EZH2 in PVB group was significantly lower than that in group TP(P<0.05).Conclusion Neoadjuvant chemotherapy of cervical cancer PVB may reduce the expression level of serum EZH2 and reduce the lesion,which could be used as an index to evaluate the efficacy of neoadjuvant chemotherapy for cervical cancer.